Skip to main content

Table 2 Treatment characteristics

From: Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung—prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT

Total dose (Gy)  
Primary tumor  
  Group 1 (PT-Ø* < 2.5 cm, n = 17) 73.8
  Group 2 (2.5 – 4.5 cm, n = 52) 79.2
  Group 3 (4.5 – 6.0 cm, n = 20) 84.6
  Group 4 (> 6.0 cm, n = 8) 90.0
Nodes 61.2
Nodes electively** 45
Fractional dose (Gy) 1.8 bid
  Interval 8 h
Radiation treatment duration (days, median, range) 30 (28 – 37)
Chemotherapy before radiotherapy (patients, %) 91 (91)
  Cycles (n, median, range) 2 (1 – 4)
  Carboplatin 76 (76)
  Cisplatin 15 (15)
  Gemcitabine 40 (40)
  Pemetrexed 36 (36)
  Navelbine 12 (12)
  Etoposide 2 ( 2)
  Taxotere 1 ( 1)
Durvalumab, consolidation post radiotherapy (patients, %)  
  Started 36 (36)
  Completed at 12 months, without toxicity 11 (11)
  Incomplete, until now well tolerated 12 (12)
  Premature termination 13 (13)
    PD-L1-negativity 4 (4)
    Progression of disease 4(4)
    Toxicity 2 (2)
    Intercurrent death 2 (2)
    Patient request 1 (1)
  1. *PT–Ø = Diameter of the primary tumor (mean of three perpendicular diameters);
  2. **To a restricted nodal volume